Drug intelligence / Profile preview

NIDB-3103

Development stage: Preclinical
Lead developer: discoveric bio group
Modality: Antibody-Based Therapeutics

Overview

NIDB-3103 is a drug candidate developed by discoveric bio group (formerly discoveric bio alpha AG). It is described as a fully human bi- and multi-specific antibody, specifically a κλ body. The drug is currently in the discovery phase, with clinical candidate selection anticipated in Q3 2025, and is being investigated for its potential in treating Parkinson's disease.

Beyond the preview

Go deeper on NIDB-3103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIDB-3103.

Explore the full profile